GlobeNewswire Inc | Feb 18, 2021 07:30AM EST

February 18, 2021

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET.

To join the call:

-- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. -- All participants should ask to be connected to the Intellia Therapeutics conference call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the companys website at www.intelliatx.com, beginning on February 25, 2021 at 12 p.m. ET.

About Intellia TherapeuticsIntellia Therapeuticsis a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellias combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more aboutIntellia and CRISPR/Cas9 atintelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:Glenn GoddardChief Financial Officer+1-857-706-1056glenn.goddard@intelliatx.com

Media:Julie FergusonInterim Head of External Affairs & Communications+1-312-385-0098julie.ferguson@intelliatx.com